	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	2,272	2,725	3,245	3,660	2,769	2,803	2,710	3,167	3,609	4,261	4,734	5,140	5,103	5,473	5,675
Cost of Operating Revenue	1,507	1,797	2,150	2,444	1,609	1,677	1,636	1,725	2,004	2,551	2,763	2,946	3,035	3,537	3,472
Gross Profit	765	928	1,095	1,216	1,160	1,126	1,074	1,442	1,605	1,710	1,972	2,194	2,069	1,937	2,204
Gross Margin	33.7	34.1	33.7	33.2	41.9	40.2	39.6	45.5	44.5	40.1	41.6	42.7	40.5	35.4	38.8
Total Operating Expenses	2,060	2,406	2,869	3,167	2,355	2,413	2,328	2,717	2,946	3,521	3,984	4,293	4,202	4,867	4,895
Operating Profit	213	319	376	494	414	390	382	450	663	740	750	847	902	606	780
Operating Margin	9.4	11.7	11.6	13.5	15.0	13.9	14.1	14.2	18.4	17.4	15.8	16.5	17.7	11.1	13.7
Financing Income/(Expense) - Net	14	41	65	60	43	37	7	19	13	20	23	22	43	59	-20
Profit before Taxes	204	1,563	441	574	482	448	404	480	583	795	847	990	941	707	855
Income Taxes	65	402	151	191	167	157	104	143	109	301	202	232	201	139	166
Profit after Tax	139	1,162	290	383	315	291	300	337	475	493	645	758	741	568	689
PAT Margin	6.1	42.6	8.9	10.5	11.4	10.4	11.1	10.6	13.1	11.6	13.6	14.8	14.5	10.4	12.1
EPS - Basic - ex Extraordinary Items	35.19	294.11	75.14	104.59	87.34	82.31	86.16	98.18	105.58	109.72	143.58	168.71	164.77	126.38	153.35
EPS - Diluted - ex Extraordinary Items	35.19	294.11	75.14	104.59	87.34	82.31	86.16	98.18	105.58	109.72	143.58	168.71	164.77	126.38	153.35
EBIT	213	319	376	494	414	390	382	450	663	740	750	847	902	606	780
EBITDA	258	365	427	519	438	419	414	493	728	813	814	926	975	691	874
EBITDA Margin	11.3	13.4	13.1	14.2	15.8	14.9	15.3	15.6	20.2	19.1	17.2	18.0	19.1	12.6	15.4

Balance Sheet

Abridged

Understanding Balance Sheet

Bayer CropScience Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	IR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	1,498	1,992	1,853	2,345	2,022	2,374	2,076	2,780	3,014	3,544	3,576	3,896	3,906	4,472	4,918
Long-Term Investments	4	4	3	32	31	31	30	31	31	30	26	26	25	25	29
Property Plant & Equipment - Net	255	343	443	293	295	306	301	414	440	401	450	431	383	427	406
Total Non-Current Assets	343	423	534	405	415	451	459	769	821	695	777	782	692	774	781
Total Assets	1,841	2,415	2,387	2,750	2,437	2,825	2,535	3,549	3,836	4,239	4,353	4,679	4,597	5,246	5,699
Total Current Liabilities	1,012	436	595	569	522	683	662	1,188	1,139	1,571	1,659	1,778	1,597	2,224	2,568
Long Term Debt	-	-	-	-	-	-	-	-	14	14	52	36	21	62	39
Total Non-Current Liabilities	36	48	50	70	75	86	95	122	124	118	169	189	150	172	166
Total Liabilities	1,048	484	645	639	597	769	757	1,310	1,263	1,689	1,829	1,967	1,748	2,396	2,734
Total Shareholders' Equity	793	1,931	1,742	2,111	1,839	2,057	1,778	2,239	2,573	2,550	2,524	2,712	2,849	2,850	2,966
Total Equity	793	1,931	1,742	2,111	1,839	2,057	1,778	2,239	2,573	2,550	2,524	2,712	2,849	2,850	2,966
Total Liabilities & Equity	1,841	2,415	2,387	2,750	2,437	2,825	2,535	3,549	3,836	4,239	4,353	4,679	4,597	5,246	5,699

Cash Flow

Abridged

Understanding Cash Flow Statement

Bayer CropScience Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	187	303	356	430	349	357	368	366	666	720	638	764	940	656	796
Working Capital - Increase/(Decrease)	-64	-120	3	-167	-87	-151	-225	90	28	-7	-406	-141	34	-355	301
Net CF from Operating Activities	123	183	360	263	261	206	143	456	694	713	231	623	974	300	1,097
Capital Expenditures - Net	50	-646	159	-97	37	49	42	55	28	31	47	73	39	40	64
Net CF from Investing Activities	70	381	-369	422	-44	-58	13	-443	-60	-22	44	58	-30	39	41
Dividends Paid - Cash - Total	16	17	20	35	62	60	60	126	102	516	673	561	607	561	563
Stock - Issuance/(Retirement) - Net	-	-	-455	-	-510	-	-505	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-109	-	-	-	-	-	-	-	-23	-37	-26	-41	-42	-49	-49
Net Cash Flow from Financing Activities	-127	-19	-478	-41	-585	-72	-577	-153	-146	-553	-699	-602	-649	-611	-611
Free Cash Flow to Equity	-35	828	200	360	224	157	101	402	644	645	158	510	893	211	984
Free Operating CF net dividend	49	-8	178	177	159	91	39	270	552	155	-497	-15	322	-302	470
Free Operating CF	65	9	198	212	221	151	99	396	653	671	176	546	929	259	1,032

Business Segment Analysis

FY End:

Mar 25

Bayer CropScience Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Agri Care (100.0%)₹ 40.90 Cr

Revenue / Sales

Agri Care (100.0%)₹ 5,473.40 Cr

Assets

Agri Care (100.0%)₹ 5,245.90 Cr

Operating Income

Agri Care (100.0%)₹ 606.10 Cr

Regional Segment Analysis

FY End:

Mar 25

Bayer CropScience Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (95.2%)₹ 5,211.90 CrGermany (1.7%)₹ 92.70 CrBangladesh (1.7%)₹ 91.30 CrOthers (1.4%)₹ 77.50 Cr

Historical Segment Analysis

Track how Bayer CropScience Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Agri Care	41	42	55	77	46	41

Frequently Asked Questions

What is the revenue of Bayer CropScience Ltd.?

The latest trailing twelve month revenue of Bayer CropScience Ltd. is ₹ 5,675.00 Cr, reflecting a 1-year growth of 3.68% and a 3-year CAGR of 3.36%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Bayer CropScience Ltd.?

The latest trailing twelve month net profit (PAT) of Bayer CropScience Ltd. is ₹ 689.20 Cr, with a 3-year earnings CAGR of -3.13%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Bayer CropScience Ltd.?

The trailing twelve month EBITDA of Bayer CropScience Ltd. is approximately ₹ 779.70 Cr (based on an operating margin of 13.74%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Bayer CropScience Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Bayer CropScience Ltd. is 153.35. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Bayer CropScience Ltd.?

The debt-to-equity ratio of Bayer CropScience Ltd. stands at 0.03. The interest coverage ratio is 39.38x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Bayer CropScience Ltd.?

The estimated book value per share of Bayer CropScience Ltd. is 657.23 (derived from a P/B ratio of 6.30 and market price of ₹ 4,139.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Bayer CropScience Ltd.?

The trailing twelve month operating cash flow of Bayer CropScience Ltd. is ₹ 1,096.80 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Bayer CropScience Ltd. report consolidated or standalone financials?

Bayer CropScience Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.